Advancements in the Management of R/R AML: ASH 2024 - Episode 6
Adverse Event Management and Patient Safety With Revumenib
Panelists discuss the most commonly seen adverse effects (AEs) in menin inhibitor treatment, strategies for managing and mitigating these AEs to optimize outcomes, and how they compare across approved and pipeline menin inhibitors, along with best practices for clinicians to manage differentiation syndrome, a critical safety concern.
Video content above is prompted by the following:
- What AEs are most commonly seen and how do you mitigate or manage these to optimize outcomes and maintain treatment continuity?
- Do these AEs align with what you’d expect when treating these patients?
- How do they compare across both approved and pipeline menin inhibitors?
- Differentiation syndrome, while manageable, is a critical safety concern,. hHow can clinicians best prepare to manage this?
Related Content:
